Table 3.
Relationship of cancer- and host-related characteristics with progression-free survival (PFS) in 109 patients with ovarian clear cell carcinoma
| Characteristics | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Age (yr) (≥50 vs. <50) | 1.561 (0842-20896) | 0.158 | ||
| FIGO stage (III/IV vs. I/II) | 8.239 (3.994-16.995) | < 0.001 | 4.027 (1.756-9.233) | 0.001 |
| LN metastasis (Yes vs. No) | 2.640 (1.333-5.229) | 0.005 | 1.367 (0.575-3.254) | 0.479 |
| Malignant ascites (Yes vs. No) | 3.604 (1.929-6.733) | 0.003 | 0.992 (0.283-3.477) | 0.990 |
| Endometriosis (No vs. Yes) | 4.232 (1.307-13.697) | 0.018 | 2.685 (0.968-5.667) | 0.155 |
| CA-125 (Unit/mL) (≥88.2 vs. <88.2) | 3.567 (1.838-8.924) | 0.005 | 1.769 (0.659-4.746) | 0.257 |
| Residual mass (≥1 cm vs. <1 cm) | 4.577 (2.392-8.757) | < 0.001 | 2.540 (1.084-5.948) | 0.032 |
| Platinum response (Resistant vs. Sensitive) | 10.105 (5.227-19.535) | < 0.001 | 3.595 (1.458-8.861) | 0.005 |
| NLR (≥2.3 vs. <2.3) | 3.495 (1.466-8.331) | 0.005 | 1.810 (0.714-4.587) | 0.211 |
| LMR (<4.2 vs. ≥4.2) | 3.065 (1.416-6.634) | 0.004 | 1.251 (0.689-3.716) | 0.427 |
| PLR (≥123.6 vs. <123.6) | 1.974 (0.703-5.539) | 0.197 | ||
HRs was obtained from Cox's proportional hazard model. HR, hazard ratio; CI, confidence interval; NLR, neutrophil-lymphocyte ratio; LMR, lymphocyte-monocyte ratio; PLR, platelet-lymphocyte ratio; FIGO, The International Federation of Gynecology and Obstetrics; LN, lymph node; CA-125, cancer antigen 125